All patients
Age < 65y (younger) Age > 65y Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (never) stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mNSCLC - L1 - all population, anti-PD-(L)1 vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results EMPOWER lung1 (all population), 2021 0.68 [0.53; 0.87]
MYSTIC (D ; all population), 2020 0.96 [0.81; 1.13]
ORIENT-11, 2020 0.61 [0.40; 0.93]
0.76 [0.57 ; 1.02 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 3 73% 1,853 moderate not evaluable progression or deaths (PFS)detailed results EMPOWER lung1 (all population), 2021 0.59 [0.49; 0.72]
ORIENT-11, 2020 0.48 [0.36; 0.64]
0.55 [0.45 ; 0.67 ] EMPOWER lung1 (all population), 2021, ORIENT-11, 2020 2 27% 1,107 moderate not evaluable objective responses (ORR)detailed results EMPOWER lung1 (all population), 2021 2.21 [1.58; 3.10]
ORIENT-11, 2020 2.54 [1.63; 3.97]
2.33 [1.78 ; 3.04 ] EMPOWER lung1 (all population), 2021, ORIENT-11, 2020 2 0% 1,107 moderate not evaluable AE (any grade)detailed results EMPOWER lung1 (all population), 2021 0.18 [0.12; 0.27]
MYSTIC (D ; all population), 2020 0.59 [0.31; 1.13]
ORIENT-11, 2020 1.02 [0.03; 30.46]
0.35 [0.12 ; 1.00 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 3 79% 1,815 moderate not evaluable AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.19 [0.13; 0.29]
MYSTIC (D ; all population), 2020 0.81 [0.60; 1.10]
ORIENT-11, 2020 1.13 [0.74; 1.73]
0.56 [0.21 ; 1.52 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 3 95% 1,815 moderate not evaluable AE leading to death (grade 5)detailed results EMPOWER lung1 (all population), 2021 1.24 [0.46; 3.38]
MYSTIC (D ; all population), 2020 0.82 [0.38; 1.75]
ORIENT-11, 2020 0.31 [0.11; 0.90]
0.71 [0.34 ; 1.46 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 3 45% 1,815 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results EMPOWER lung1 (all population), 2021 1.62 [0.82; 3.21]
MYSTIC (D ; all population), 2020 0.72 [0.47; 1.12]
ORIENT-11, 2020 0.70 [0.31; 1.55]
0.92 [0.54 ; 1.54 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 3 52% 1,815 moderate not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.10 [0.64; 1.89]
ORIENT-11, 2020 0.64 [0.26; 1.56]
0.95 [0.59 ; 1.53 ] MYSTIC (D ; all population), 2020, ORIENT-11, 2020 2 5% 1,118 moderate not evaluable STRAE (any grade)detailed results MYSTIC (D ; all population), 2020 0.56 [0.35; 0.90]
0.56 [0.35 ; 0.90 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable STRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.48 [0.28; 0.84]
0.48 [0.28 ; 0.84 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable TRAE (any grade)detailed results MYSTIC (D ; all population), 2020 0.24 [0.17; 0.34]
0.24 [0.17 ; 0.34 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.34 [0.24; 0.49]
0.34 [0.24 ; 0.49 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable TRAE leading to death (grade 5)detailed results MYSTIC (D ; all population), 2020 0.63 [0.11; 3.82]
0.63 [0.11 ; 3.82 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable TRAE leading to discontinuation (any grade)detailed results MYSTIC (D ; all population), 2020 0.55 [0.31; 0.99]
0.55 [0.31 ; 0.99 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.28 [0.60; 2.75]
1.28 [0.60 ; 2.75 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
1.91 [0.06 ; 57.12 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Alopecia TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Anaemia TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.01 [0.00; 0.19]
0.01 [0.00 ; 0.19 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Asthenia TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.12 [0.01; 0.94]
0.12 [0.01 ; 0.94 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Colitis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
1.42 [0.11 ; 18.58 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 0% 1,418 moderate not evaluable Constipation TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.48 [0.02; 14.24]
0.48 [0.02 ; 14.24 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.24 [0.03; 2.13]
0.24 [0.03 ; 2.13 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Diabetes TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
MYSTIC (D ; all population), 2020 0.95 [0.13; 6.81]
ORIENT-11, 2020 0.49 [0.01; 24.91]
0.74 [0.16 ; 3.54 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 3 0% 1,815 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.81 [0.27; 2.45]
0.81 [0.27 ; 2.45 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
1.92 [0.17 ; 21.22 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 0% 1,418 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
ORIENT-11, 2020 0.49 [0.01; 24.91]
0.77 [0.08 ; 7.39 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 3 0% 1,815 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
MYSTIC (D ; all population), 2020 3.83 [0.17; 85.25]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.48 [0.19 ; 11.68 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 3 0% 1,815 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.75 [0.15 ; 19.96 ] EMPOWER lung1 (all population), 2021, ORIENT-11, 2020 2 0% 1,094 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.07 [0.08 ; 14.02 ] EMPOWER lung1 (all population), 2021, ORIENT-11, 2020 2 0% 1,094 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Nausea TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.08 [0.00; 1.41]
0.08 [0.00 ; 1.41 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Nephritis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.96 [0.06 ; 15.36 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 0% 1,418 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.02 [0.00; 0.18]
0.02 [0.00 ; 0.18 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
MYSTIC (D ; all population), 2020 3.85 [0.43; 34.59]
ORIENT-11, 2020 0.98 [0.09; 10.96]
2.05 [0.47 ; 8.85 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 3 0% 1,815 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
ORIENT-11, 2020 0.49 [0.01; 24.91]
0.68 [0.04 ; 10.98 ] MYSTIC (D ; all population), 2020, ORIENT-11, 2020 2 0% 1,118 moderate not evaluable Rash TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
ORIENT-11, 2020 0.16 [0.02; 1.56]
1.08 [0.14 ; 8.52 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 3 51% 1,815 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.03 [0.00; 0.42]
0.03 [0.00 ; 0.42 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Vomiting TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.07 [0.00; 1.18]
0.07 [0.00 ; 1.18 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
0.24 [0.01 ; 5.34 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Alopecia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.41 [0.04 ; 4.65 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 0% 1,418 moderate not evaluable Anaemia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.03 [0.01; 0.13]
MYSTIC (D ; all population), 2020 0.16 [0.07; 0.34]
0.08 [0.02 ; 0.38 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 73% 1,418 moderate not evaluable Arthralgia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Asthenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
MYSTIC (D ; all population), 2020 0.95 [0.41; 2.23]
0.92 [0.40 ; 2.08 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 0% 1,418 moderate not evaluable Back pain AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
MYSTIC (D ; all population), 2020 0.32 [0.03; 3.05]
0.36 [0.05 ; 2.37 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 0% 1,418 moderate not evaluable Blood creatinine increased AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Constipation AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
MYSTIC (D ; all population), 2020 0.95 [0.06; 15.31]
0.96 [0.10 ; 9.22 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 0% 1,418 moderate not evaluable Cough AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
1.91 [0.06 ; 57.12 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Decreased appetite AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.06; 15.46]
MYSTIC (D ; all population), 2020 1.44 [0.40; 5.14]
1.34 [0.42 ; 4.27 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 0% 1,418 moderate not evaluable Diarrhoea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.16 [0.02; 1.32]
MYSTIC (D ; all population), 2020 0.38 [0.07; 1.96]
0.27 [0.07 ; 1.00 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 0% 1,418 moderate not evaluable Dyspnoea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.17; 21.41]
MYSTIC (D ; all population), 2020 1.61 [0.58; 4.47]
1.65 [0.64 ; 4.24 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 0% 1,418 moderate not evaluable Fatigue AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.72 [0.16; 3.24]
MYSTIC (D ; all population), 2020 1.20 [0.47; 3.07]
1.04 [0.47 ; 2.31 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 0% 1,418 moderate not evaluable Febrile neutropenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.06 [0.00; 1.03]
0.06 [0.00 ; 1.03 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Hypertension AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
0.24 [0.01 ; 5.34 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Increase AST AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 4.87 [0.57; 41.91]
4.87 [0.57 ; 41.91 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Increased ALT AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 5.82 [0.29; 116.64]
5.82 [0.29 ; 116.64 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Increased Lipase Level AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Leucopenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.10 [0.01; 0.83]
0.10 [0.01 ; 0.83 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable myocarditis AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
0.96 [0.02 ; 48.69 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Nausea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.12 [0.01; 2.26]
MYSTIC (D ; all population), 2020 0.16 [0.02; 1.31]
0.14 [0.03 ; 0.80 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 0% 1,418 moderate not evaluable Neutropenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.05 [0.01; 0.21]
MYSTIC (D ; all population), 2020 0.07 [0.02; 0.24]
0.06 [0.02 ; 0.15 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 0% 1,418 moderate not evaluable Pancytopenia (AE grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.06; 15.46]
0.96 [0.06 ; 15.46 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Peripheral sensory neuropathy AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Pneumonia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.77 [0.20; 2.88]
0.77 [0.20 ; 2.88 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Pneumonitis AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Pruritus AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Pyrexia AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 5.76 [0.29; 115.45]
5.76 [0.29 ; 115.45 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Rash AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 5.82 [0.29; 116.64]
MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
3.72 [0.61 ; 22.69 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 0% 1,418 moderate not evaluable Rash maculopapular AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.93 [0.06 ; 57.70 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Stomatitis AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.02 [0.00; 0.30]
MYSTIC (D ; all population), 2020 0.05 [0.01; 0.38]
0.04 [0.01 ; 0.18 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 0% 1,418 moderate not evaluable Vomiting AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.12 [0.01; 2.26]
MYSTIC (D ; all population), 2020 0.54 [0.16; 1.86]
0.43 [0.14 ; 1.35 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 0% 1,418 moderate not evaluable Weight decreased AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
2.54 [0.39 ; 16.78 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020 2 0% 1,418 moderate not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-01 12:38 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 36
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563